There is no cure for spinal muscular atrophy (SMA). It happens when both copies of the SMN1 gene are faulty, so the nerve cells that control muscles slowly die. Since 2016 the FDA has approved medicines that raise the missing SMN protein: Spinraza, Zolgensma, Evrysdi and, in November 2025, Itvisma. They can slow or stop the disease, and results are best when treatment starts before symptoms, which is why every U.S. state now screens newborns. On September 11, 2026 the FDA added Isembyld, which works on muscle instead. Our view: these treatments change the outlook, but they don't bring back nerve cells already lost, so a cure would need to repair that damage too.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with an SMA-experienced medical team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your SMA care team.
For babies with only two SMN2 copies, could part of the damage that newborn treatment cannot undo happen in the last weeks before birth? If so, a carefully studied treatment that starts before birth and continues after it might help more of these children develop like their peers. Treatment during pregnancy is not an approved use and should only be explored in carefully run research.
What would prove it wrong: if babies with two SMN2 copies treated before birth do no better in movement than similar babies treated in their first days of life.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In a small exploratory study, 15 wheelchair users with SMA did 10 minutes of assisted interval cycling five times a week at home for 8 weeks. Attendance was 95%, no one dropped out because of the exercise, and fatigue did not clearly increase. But the researchers saw no clinically meaningful changes in symptoms, motor performance or blood measures. It shows this kind of exercise was doable, not that it helps.
A re-analysis of walking data from two people with SMA who could walk found that after 4 weeks of epidural spinal cord stimulation they walked farther and faster, with more hip movement (up to 48% more range of motion). With only two people, this is a very early signal. The authors say larger studies are needed.
A panel of 19 UK specialists (18 voters) used a structured voting process (modified Delphi, April to June 2025) on 22 statements about people with SMA who need permanent ventilation. All 22 reached consensus (89% to 100% agreement). They agreed that needing a ventilator alone should not block access to disease-modifying drugs, and that benefit should be judged more broadly, including small gains in function and quality of life. This is expert opinion, not a trial result. It was funded by Roche, and one author works for Roche.
Between January 2020 and the end of 2025, 1,502,890 Canadian babies were screened. 120 had SMA, about 1 in 12,524 births. Screening methods, the timing of SMN2 copy-number reports and drug coverage differ by province. Babies with 4 SMN2 copies face the least equal access to treatment. This is a survey-based quality report, not a trial.
A group of pediatric neurology experts published a consensus on monitoring after intrathecal onasemnogene abeparvovec (Itvisma). It adds checks for possible nerve-cell (dorsal root ganglia) side effects and calls for long-term follow-up and a planned move to adult neurology care. This is a guideline, not a new trial result.
Scholar Rock refiled its European application for apitegromab (Isembyld) on October 8, 2026, naming a different fill-finish plant (the final step that puts the medicine in vials). It had withdrawn the first application in August after saying the earlier plant, Catalent Indiana, lacked GMP (manufacturing quality) compliance. The company expects an EMA committee opinion in the first half of 2027. It is not approved in Europe. This is a company announcement.
The UK government says the NHS is introducing SMA screening for newborns through a phased evaluation beginning in October 2026. The page does not say which areas go first. Screening lets babies be treated early, which this report's evidence shows matters. This is a policy step, not a trial result.
In a caregiver-reported survey of 73 children, 73.2% of those treated before 90 days of age walked independently, compared with 36.7% of those treated later. Scoliosis was less common too (24.4% vs 62.5%). Presented at the 2026 AANEM meeting. It is survey data, not a clinical trial, and the groups were not randomized.
Approved for people 2 and older who already take an SMN2-targeted treatment (nusinersen or risdiplam). In the 188-person SAPPHIRE trial, children aged 2–12 on 10 mg/kg improved 2.2 points more than placebo on the HFMSE motor scale at one year. The label warns of serious fractures. The peer-reviewed SAPPHIRE paper appeared in Lancet Neurology in 2025.
Biogen's salanersen, a spinal-injection medicine being tested as a once-a-year dose, is in three Phase 3 trials: SOLAR in people aged 15 to 60 (started September 8, 2026), STELLAR-2 in babies (September 4, 2026), and STELLAR-1 in babies treated before symptoms (April 28, 2026).
Scholar Rock withdrew its application to the European Medicines Agency for apitegromab (Isembyld) in 5q SMA on August 13, 2026. The EMA summary gives no reason. The medicine is approved in the United States but not in the EU.
The European Commission authorized intrathecal onasemnogene abeparvovec for 5q SMA in people 2 years and older, after a positive EMA opinion on April 23, 2026.
After a managed-access period, NICE recommended both medicines for routine use, with NHS England funding from May 14, 2026, under conditions such as not combining the two.
A faster, higher-dose schedule: two 50 mg loading doses 14 days apart, then 28 mg every 4 months. In the DEVOTE trial (published in Nature Medicine), infants on the high dose gained 15.1 points on a motor test at 6 months, while matched untreated infants from an earlier trial lost 11.1 points.
In a letter to the SMA community, Genentech said the anti-myostatin antibody, tested with risdiplam in Part 1 of the MANATEE trial, did not consistently improve muscle growth or motor function over risdiplam alone. The company said the decision was not due to safety findings. Company source; full data not yet published.
STEER (126 treatment-naive people aged 2–17) met its main goal, with motor scores 1.88 points better than sham. STRENGTH (27 people who switched from nusinersen or risdiplam) found safety similar to STEER. Both appeared in Nature Medicine.
Four FDA-approved medicines raise SMN protein, and one newer medicine builds on them by working on muscle. None is a cure. Supportive care for breathing, feeding and movement is still essential.
Helps the SMN2 backup gene make more working SMN protein. It is given into the spinal fluid every 4 months after loading doses. A high-dose schedule (two 50 mg loading doses, then 28 mg every 4 months) was approved by the FDA on March 27, 2026.
A gene therapy that delivers a working copy of the SMN gene. It carries a boxed warning for serious liver injury, so liver tests are needed for at least three months after treatment.
A daily medicine that boosts SMN protein from SMN2. A 5 mg tablet was approved on February 11, 2025, in addition to the liquid. The most common side effects in later-onset SMA were fever, diarrhea and rash.
The same gene therapy as Zolgensma at one fixed dose, given into the spinal fluid. In the Phase 3 STEER trial (126 people aged 2–17 who could sit but had never walked), motor scores improved by 1.88 points more than with a sham procedure.
The first SMA medicine aimed at muscle. In the SAPPHIRE trial, 34.2% of children aged 2–12 on the approved dose improved by 3 or more points on a motor scale, compared with 13.5% on placebo. The label warns of serious bone fractures.
International care guidelines cover physical therapy, positioning and stretching, orthopedic and spine care, and nutrition and swallowing support, delivered by a team.
| Treatment | For | What it does |
|---|---|---|
| Nusinersen (Spinraza) | Children and adults | Raises SMN protein from SMN2. Spinal injection every 4 months after loading doses. |
| Risdiplam (Evrysdi) | Children and adults | Raises SMN protein from SMN2. Liquid or tablet by mouth, once a day. |
| Onasemnogene abeparvovec (Zolgensma) | Under age 2 | One-time IV gene therapy. Liver monitoring needed afterward. |
| Onasemnogene abeparvovec-brve (Itvisma) | Ages 2 and older | One-time gene therapy given into the spinal fluid. |
| Apitegromab (Isembyld) | Ages 2+ on an SMN2 treatment | Add-on that blocks myostatin to support muscle. IV every 4 weeks. |
| Team supportive care | Everyone | Physical therapy, nutrition, orthopedic and spine care. |
No supplement treats SMA. The daily care that helps most is physical therapy, good nutrition and support for breathing and the spine. We rate each by the strength of evidence.
International SMA care guidelines recommend regular therapy, stretching, bracing and positioning to protect joints and function.
The same guidelines call for checks on growth, swallowing and feeding, since both under- and overweight are common.
A Cochrane review found the evidence on exercise in SMA type 3 too weak to judge. A small 2025 trial of breathing-muscle training found it safe, with only a small gain in strength.
A Cochrane review found creatine probably has no meaningful effect on motor function in SMA types 2 and 3.
Tested in trials and found to probably have no meaningful benefit. Valproic acid is a prescription drug with its own risks.
Gabapentin, hydroxyurea and phenylbutyrate also showed no meaningful benefit in trials reviewed by Cochrane.
Be careful: don't delay or stop an approved SMA treatment in favor of a supplement. Tell your SMA team about every supplement you take, because swallowing problems and other medicines can change what's safe.
Centers recognized for expertise in this condition, and communities of people living with it.
Listed in the Cure SMA Care Center Network, the U.S. patient foundation's network of SMA clinics, and a site in the Phase 3 SAPPHIRE trial of apitegromab.
Listed in the Cure SMA Care Center Network and a site in the SAPPHIRE trial. It runs a dedicated pediatric SMA clinic alongside its research center.
Joined the Cure SMA Care Center Network in March 2023 and was a site in the SAPPHIRE trial.
Listed in the Cure SMA Care Center Network and a U.S. site in the Phase 3 STEER trial of intrathecal gene therapy.
Describes itself as one of only a few adult-only Cure SMA Care Center Network sites in the U.S., and is listed in Cure SMA's network.
Runs a Cure Spinal Muscular Atrophy Care Center clinic and was added to the Cure SMA Care Center Network in 2022.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Living with SMA, or caring for a child with it, is easier with people who understand. Most of these are free.
The main U.S. SMA organization, with local chapters, support for newly diagnosed families, an annual conference and a treatment-center finder.
Visit ↗The UK charity for people with SMA and their families, sharing support and plain-language trial updates.
Visit ↗Connects national SMA patient groups across Europe and shares research and treatment news.
Visit ↗Offers information on SMA, support programs and a network of neuromuscular care clinics.
Visit ↗Many private parent, caregiver and adult groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Spinraza, Zolgensma and Evrysdi are approved in the U.S., EU, Canada and Japan and recommended by NICE in England. The two newest medicines are approved only in the U.S. and, for Itvisma, the EU.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Nusinersen (Spinraza)Spinal injection | Approved 2016 | Approved 2017 | NICE 2019 | Marketed 2017 | Approved 2017 | — | — | — | — |
| Onasemnogene abeparvovec (Zolgensma)IV gene therapy | Approved 2019 | Approved 2020 | NICE 2021 | Marketed 2021 | Approved 2020 | — | — | — | — |
| Risdiplam (Evrysdi)Oral | Approved 2020 | Approved 2021 | NICE 2021 | Marketed 2021 | Approved 2021 | — | — | — | — |
| Onasemnogene abeparvovec-brve (Itvisma)Intrathecal gene therapy | Approved 2025 | Approved 2026 | — | — | — | — | — | — | — |
| Apitegromab (Isembyld)Muscle-targeted add-on | Approved 2026 | — | — | — | — | — | — | — | — |
The European Commission authorized the intrathecal gene therapy for people 2 and older with 5q SMA. It is under additional monitoring, as new medicines are.
After years of managed access, NICE moved both medicines into routine NHS funding, using evidence gathered from people treated in England.
Three Phase 3 trials are recruiting to test a once-a-year spinal injection in babies, teens and adults.
SMA is inherited. A child gets it when both copies of the SMN1 gene don't work. Without enough SMN protein, motor neurons in the spinal cord die, and the muscles they control weaken.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations help families affected by SMA pay for equipment, travel and medicines. Funds are limited and rules vary, so contact each one directly.
Grants of $250 to $2,500 toward items insurance and public programs don't cover, such as wheelchair repairs, home changes, accessible vehicles, assistive technology, medical equipment and funeral costs. Grants cover only part of a cost, and you or others must also be raising money for the same item.
See the grant ↗One grant helps with travel to a regional neuromuscular centre for NHS-funded SMA drug treatment (up to £500 a year). The other pays toward items that support independence (up to £800 a year), paid straight to the supplier.
See FlexiGrants ↗Up to $1,000 a year toward equipment such as wheelchairs, lifts, hospital beds, breathing devices and communication devices, paid to the vendor. It doesn't pay back past purchases or cover permanent home or vehicle changes.
See the program ↗Helps pay for equipment not available free elsewhere, such as ramps, bathroom aids, hospital beds, breathing machines, power wheelchairs and repairs. Items under $200 aren't covered, and you need approval before buying. Coverage varies by province.
See the program ↗Helps with equipment and home changes that insurance or the Medicaid Waiver won't cover, such as wheelchairs, bathroom changes and van conversions. Most awards are under $10,000, and it doesn't pay back past purchases.
See the program ↗Grants toward copays, coinsurance, deductibles and insurance premiums. The fund was listed as open on October 6, 2026, but funds can run out.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually cited: that treatments don't restore motor neurons already lost, that most current medicines target SMN2, and the general descriptions of when each SMA type starts, which reflect the established medical literature and MedlinePlus. FDA approval dates come from Drugs@FDA (Spinraza high dose: March 27, 2026, although news reports and the MDA release are dated March 30) and FDA's biologics pages for Zolgensma and Itvisma. The STEER difference is given as 1.88 points from the peer-reviewed paper; some news reports instead quote the two groups' raw changes (2.39 vs 0.51). The Isembyld trial numbers come from the FDA label. The emugrobart decision rests on a company letter, and full MANATEE data have not been published. "NICE" cells mean NICE recommended the medicine for NHS use in England, not a separate MHRA approval date. "Marketed" cells for Canada use Health Canada's first-marketed date, not the approval date. The Japan Spinraza date comes from a news report, and the Japan Zolgensma and Evrysdi dates from company releases. All "—" cells are unverified. Itvisma and Isembyld approvals outside the U.S. and EU could not be confirmed. No SMA Reddit community is listed because we could not open Reddit to confirm one. Expert care centers: the Cure SMA Care Center Network is an official patient-foundation designation, but its full published list dates from August 2022 (plus a March 2023 addition), and Cure SMA's live map could not be read, so current membership was not rechecked for every site. Boston Children's own page blocked automated access. Financial help: checked October 6, 2026, mostly with a headless browser. The Gwendolyn Strong Foundation's pages disagree on timing (rolling vs. spring and fall reviews). SMA UK's page doesn't say UK-only but describes NHS treatment. TotalAssist (where PAN Foundation's copay funds moved in 2026) blocked a second check, so its open status comes from the first reading that day. Left out: Cure SMA's equipment pool and travel kits (items, not money), Good Days' SMA fund (closed), Laughing At My Nightmare (its pages don't name SMA, and its 2026 cycles were closed), Muscular Dystrophy UK's Joseph Patrick Trust (paused), and the Fighting for Kaiden Foundation (its site would not load).